Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.

Huma, Camden Health Partners and UCLPartners launch digital-first population health programme to identify and manage cardiovascular disease

08.02.2023, 4556 Zeichen
London (ots/PRNewswire) - Huma Therapeutics ("Huma"), a leading global digital health company, today announced a partnership with Camden Health Partners and UCLPartners to deliver a digital-first programme aimed at identifying more people living in North Central London who are at high risk of, or who have undiagnosed, cardiovascular disease (CVD) and helping them to adopt new behaviours to help modify the condition. The programme will form a blueprint for potential national adoption.
* Aim is to prevent avoidable heart attacks and strokes in North London
* Expands primary care capacity by utilising digital tools to identify and manage high risk individuals
* Advances proactive, predictive care for people at risk of the world's leading cause of death1
Supported by a grant from the Small Business Research Initiative (SBRI) Healthcare, the initiative aligns with the government's review-driven2 plans to digitise the existing National Health Service (NHS) Health Check, making it more convenient for patients to carry out the checks at home and reduce pressure on GPs3.
People at risk of, or with, CVD are typically identified during an NHS Health Check. These checks require considerable face-to-face healthcare resources, and some remain incomplete because individuals do not follow through with appointments to measure biomarkers such as blood tests. The digital-first programme aims to expand the Health Check system by:
* prompting individuals to complete appointments linked to the Health Check through Huma's iPLATO multi-channel engagement platform
* moving the majority of the Health Check to a digital format on Huma's remote patient monitoring platform, reducing in-person appointment duration and thereby increasing population screening capacity
* driving access to online, approved materials which recommend lifestyle changes in line with improving CVD status
* providing enhanced access to face-to-face health checks for those who do not wish to use digital tools, to avoid digital exclusion
Dan Vahdat, CEO and Founder of Huma, said "We are proud to be part of the global movement that is bringing health equity through digital technology to people everywhere. Imagine the impact we could make by reaching tens of thousands of people across London alone who may be at risk of cardiovascular disease, making them aware of cardiovascular health, helping educate them and encouraging them to connect with their clinicians. This is the very definition of proactive care and I am so excited that, together with our clinical partners, we have the opportunity to scale our evidence-based digital innovations to advance personalised health."
Dr Alex Warner, Clinical Director at Camden Health Partners, said, "As Camden GPs we are excited about the potential for this programme. We know that there are many of our patients with modifiable cardiovascular risk factors, but within our current practice we have struggled to find the capacity to identify and support them. This new digital-first approach, powered by Huma's technology will allow our patients to be better-informed and empowered to improve their health, and to prevent more heart attacks and strokes across our diverse Camden population."
Kate Cheema, Director of Evaluation and Insights at UCLPartners, added: "UCLPartners is delighted to be working with HUMA as an evaluation partner. CVD is a leading cause of disease and inequality across London and we are looking forward to bringing together staff, patient and stakeholder experience and expertise to demonstrate real improvements for people living with, and at risk of CVD, and to ensuring critical lessons learned are fed back into the healthcare system for the benefit of all."
Tobias Alpsten, Founder and CEO of iPLATO Healthcare, a Huma company, added: "We are delighted to be part of this ground-breaking initiative which, in partnership with local GP practices, will use the myGP Engagement Hub to recruit patients to this CVD pathway transformation programme."
CVD is the world's leading cause of death according to the World Health Organization. It is the single biggest condition4 where lives can be saved by the UK's NHS over the next decade. There are 7.6 million people living with CVD in the UK, and it is a leading cause of premature disability, mortality, and health inequalities, responsible for one in four deaths each year5.
1. World Health Organization: the The top 10 causes of death
https://www.who.int/news-room/fact-sheets/detail/t... -death
Digital press kit: http://www.ots.at/pressemappe/PR167548/aom

BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Wiener Börse Plausch S4/27: Spekulatives zu Kapsch und Bawag, dieser Podcast erstmals Nr. 1 in den Apple Charts für Österreich


Aktien auf dem Radar:Addiko Bank, Bawag, Frequentis, Marinomed Biotech, AT&S, UBM, ATX, ATX Prime, ATX TR, voestalpine, Wienerberger, Erste Group, Verbund, Immofinanz, Österreichische Post, OMV, RBI, SBO, Strabag, AMS, CA Immo, DO&CO, EVN, FACC, Kapsch TrafficCom, Palfinger, Porr, Rath AG, Zumtobel, Flughafen Wien, Oberbank AG Stamm.

Random Partner

Rosinger Group
Die Rosinger Group ist einer der führenden Finanzkonzerne in Mitteleuropa und in den Geschäftsfeldern "Eigene Investments" sowie "hochspezialisierte Beratungsleistungen" aktiv. Mit bisher mehr als sechzig Börsenlistings und IPOs weltweit gehört die Rosinger Group auch an der Wiener Börse zu den maßgeblichen Playern.

>> Besuchen Sie 65 weitere Partner auf boerse-social.com/partner

Mehr aktuelle OTS-Meldungen HIER

>> mehr


Börse Social Club Board
>> mehr
    wikifolio-Trades Austro-Aktien 21-22: EVN(1)
    wikifolio-Trades Austro-Aktien 19-20: Bawag(1), Verbund(1)
    wikifolio-Trades Austro-Aktien 18-19: Verbund(2), Kontron(1), OMV(1), EVN(1)
    Star der Stunde: OMV 1.37%, Rutsch der Stunde: Zumtobel -2.35%
    wikifolio-Trades Austro-Aktien 17-18: Bawag(1), Verbund(1), AMS(1), UBM(1), Erste Group(1)
    Star der Stunde: Bawag 2.25%, Rutsch der Stunde: Kapsch TrafficCom -2.55%
    wikifolio-Trades Austro-Aktien 16-17: AT&S(1), OMV(1)
    BSN MA-Event Kapsch TrafficCom
    Star der Stunde: RHI Magnesita 0.4%, Rutsch der Stunde: Marinomed Biotech -1.92%